Figure 1
From: BHLHE40, a potential immune therapy target, regulated by FGD5-AS1/miR-15a-5p in pancreatic cancer
Expression pattern and prognostic value of BHLHE40 from the perspective of pan-cancer. (A) BHLHE40 expression levels in different tumor tissues and adjacent normal tissues from TCGA databases. (B–F) Prognostic analysis of BHLHE40 mRNA expression levels in glioblastoma (GBM), acute myeloid leukemia (LAML), brain lower grade glioma (LGG), ovarian serous cystadenocarcinoma (OV) and pancreatic adenocarcinoma (PAAD). (G) BHLHE40 mRNA expression levels in PAAD patients and normal paired sample from TCGA databases. (H–M) BHLHE40 mRNA expression levels in T stage (T3 and T4 stage vs. T1 and T2 stage), M stage, pathologic stage (stage II and III and IV vs. stage I), primary therapy outcomes (PD vs SD and PR and CR), Residual tumor (R1 and R2 vs. R0) and Anatomic neoplasm subdivision (Body and Tails and Others vs. Head).
